News

SHINE has provided the first supply of Ilumira – its non-carrier added lutetium-177 (n.c.a. Lu-177) chloride ... SHINE logo (PRNewsfoto/SHINE Technologies, LLC) ...
MELBOURNE, Australia and INDIANAPOLIS, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a new global clinical supply agreement with ...
Annual awards celebrate innovation, collaboration and excellence PLANO, Texas, Jan. 25, 2024 /PRNewswire/ -- Ribbon Communications Inc. (Nasdaq: RBBN), a global provider of real time communications ...
Blue Earth Therapeutics will leverage SHINE’s non-carrier added lutetium-177 chloride, Ilumira, in a new treatment for prostate cancer undergoing clinical trials JANESVILLE, Wis., June 6, 2024 ...
SHINE will immediately commence supply of n.c.a. 177 Lu for use in clinical trials of Telix’s therapeutic candidates TLX591 (177 Lu-rosopatamab for advanced prostate cancer) and TLX250 (177 Lu ...
Telix and SHINE partner for Lutetium-177 Supply GlobeNewswire February 10, 2022 MELBOURNE, Australia and INDIANAPOLIS, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX ...